TY - JOUR
T1 - Leukotriene B4 receptor 1 exacerbates inflammation following myocardial infarction
AU - Horii, Yuma
AU - Nakaya, Michio
AU - Ohara, Hiroki
AU - Nishihara, Hiroaki
AU - Watari, Kenji
AU - Nagasaka, Akiomi
AU - Nakaya, Takeo
AU - Sugiura, Yuki
AU - Okuno, Toshiaki
AU - Koga, Tomoaki
AU - Tanaka, Akira
AU - Yokomizo, Takehiko
AU - Kurose, Hitoshi
N1 - Funding Information:
This study was supported by grants from Grants‐in‐Aid for Scientific Research (KAKENHI) [to MN (17H03984, 17H05510) and HK (17H01525)]; from Grants‐in‐Aid for Scientific Research on Innovative Areas (25116716 to HK); from the Ono Medical Research Foundation, The Takeda Science Foundation, The Mochida Memorial Foundation for Medical and Pharmaceutical Research, SENSHIN Medical Research Foundation, The Shimabara Science Promotion Foundation, MSD Life Science Foundation, Senri Life Science Foundation (to MN); from Japan Agency for Medical Research and Development (AMED) (JP20gm5810030, JP19fk0210029 to MN); from Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP19am0101091 from Grant‐in‐Aid for JSPS Research Fellow (19J20083 to Y. H.). We appreciate for the technical supports from the Research Support Center, Graduate School of Medical Sciences, Kyushu University and from Medical Institute of Bioregulation, Kyushu University.
Funding Information:
This study was supported by grants from Grants-in-Aid for Scientific Research (KAKENHI) [to MN (17H03984, 17H05510) and HK (17H01525)]; from Grants-in-Aid for Scientific Research on Innovative Areas (25116716 to HK); from the Ono Medical Research Foundation, The Takeda Science Foundation, The Mochida Memorial Foundation for Medical and Pharmaceutical Research, SENSHIN Medical Research Foundation, The Shimabara Science Promotion Foundation, MSD Life Science Foundation, Senri Life Science Foundation (to MN); from Japan Agency for Medical Research and Development (AMED) (JP20gm5810030, JP19fk0210029 to MN); from Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP19am0101091 from Grant-in-Aid for JSPS Research Fellow (19J20083 to Y. H.). We appreciate for the technical supports from the Research Support Center, Graduate School of Medical Sciences, Kyushu University and from Medical Institute of Bioregulation, Kyushu University.
Publisher Copyright:
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Leukotriene B4 receptor 1 (BLT1), a high-affinity G-protein-coupled receptor for leukotriene B4 (LTB4), is expressed on various inflammatory cells and plays critical roles in several inflammatory diseases. In myocardial infarction (MI), various inflammatory cells are known to be recruited to the infarcted area, but the function of BLT1 in MI is poorly understood. Here, we investigated the role of BLT1 in MI and the therapeutic effect of a BLT1 antagonist, ONO-4057, on MI. Mice with infarcted hearts showed increased BLT1 expression and LTB4 levels. BLT1-knockout mice with infarcted hearts exhibited attenuated leukocyte infiltration, proinflammatory cytokine production, and cell death, which led to reduced mortality and improved cardiac function after MI. Bone-marrow transplantation studies showed that BLT1 expressed on bone marrow-derived cells was responsible for the exacerbation of inflammation in infarcted hearts. Furthermore, ONO-4057 administration attenuated the inflammatory responses in hearts surgically treated for MI, which resulted in reduced mortality and improved cardiac function after MI. Our study demonstrated that BLT1 contributes to excessive inflammation after MI and could represent a new therapeutic target for MI.
AB - Leukotriene B4 receptor 1 (BLT1), a high-affinity G-protein-coupled receptor for leukotriene B4 (LTB4), is expressed on various inflammatory cells and plays critical roles in several inflammatory diseases. In myocardial infarction (MI), various inflammatory cells are known to be recruited to the infarcted area, but the function of BLT1 in MI is poorly understood. Here, we investigated the role of BLT1 in MI and the therapeutic effect of a BLT1 antagonist, ONO-4057, on MI. Mice with infarcted hearts showed increased BLT1 expression and LTB4 levels. BLT1-knockout mice with infarcted hearts exhibited attenuated leukocyte infiltration, proinflammatory cytokine production, and cell death, which led to reduced mortality and improved cardiac function after MI. Bone-marrow transplantation studies showed that BLT1 expressed on bone marrow-derived cells was responsible for the exacerbation of inflammation in infarcted hearts. Furthermore, ONO-4057 administration attenuated the inflammatory responses in hearts surgically treated for MI, which resulted in reduced mortality and improved cardiac function after MI. Our study demonstrated that BLT1 contributes to excessive inflammation after MI and could represent a new therapeutic target for MI.
KW - inflammation
KW - leukotriene b4 receptor 1
KW - myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85084373305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084373305&partnerID=8YFLogxK
U2 - 10.1096/fj.202000041R
DO - 10.1096/fj.202000041R
M3 - Article
C2 - 32385915
AN - SCOPUS:85084373305
SN - 0892-6638
VL - 34
SP - 8749
EP - 8763
JO - FASEB Journal
JF - FASEB Journal
IS - 6
ER -